Guidance for Using Intravenous Artesunate for Treating Severe Malaria in the United States

Image of Continuing Education Credits abbreviation. = Free Continuing Education

Date: Thursday, March 28, 2019

Time: 2:00pm-3:00pm (Eastern Time)

Instructions for Obtaining Continuing Education (CE)
To receive continuing education (CE) for WC2922-032819 – (Webcast) Clinician Outreach and Communication Activity (COCA) Calls/Webinars – COCA Call– Guidance for Using Intravenous Artesunate for Treating Severe Malaria in the United States, March 28, 2019, please visit TCEO and follow these 9 Simple Steps by April 29, 2019.

To receive continuing education (CE) for WD2922-032819 – Clinician Outreach and Communication Activity (COCA) Calls/Webinars – COCA Call– Guidance for Using Intravenous Artesunate for Treating Severe Malaria in the United States, March 28, 2019 (Web on Demand), please visit TCEO and follow these 9 Simple Steps by April 30, 2021.

Overview

In the United States, an average of 1,700 cases of malaria are imported each year, of which 300 are severe. Severe malaria must be treated with an intravenous (IV) antimalarial drug. Quinidine, the only FDA-approved IV antimalarial drug, will no longer be available starting April 1, 2019. At that time, IV artesunate, the WHO-recommended first-line treatment for severe malaria, will become the first-line drug for treatment of severe malaria in the United States. Because IV artesunate is neither FDA-approved nor commercially available in the United States, CDC has made IV artesunate available under an expanded access investigational new drug (IND) protocol. Starting on April 1, 2019, all U.S. clinicians must call CDC to obtain IV artesunate to treat cases of severe malaria.

During this COCA Call, clinicians will learn about CDC’s guidance for use of IV artesunate for the treatment of severe malaria.

At the conclusion of the session, the participant will be able to accomplish the following:

  1. Cite background information on the topic covered during the presentation.
  2. Discuss CDC’s role in the topic covered during the presentation.
  3. Describe the topic’s implications for clinicians.
  4. Discuss concerns and/or issues related to preparedness for and/or response to urgent public health threats.
  5. Promote health improvement, wellness, and disease prevention in cooperation with patients, communities, at-risk populations, and other members of an interprofessional team of health care providers.

Activity Specific Objectives
At the conclusion of the session, the participant will be able to accomplish the following:

  • Identify the criteria for severe malaria.
  • Describe treatment of severe malaria, including interim treatment, and use of IV artesunate.
  • Describe how to obtain IV artesunate from CDC.

Kathrine R. Tan, MD, MPH
Chief, Domestic Response Unit, Malaria Branch
Division of Parasitic Diseases and Malaria
Center for Global Health
Centers for Disease Control and Prevention

Clive Brown, MBBS, MPH, MSc, DTM&H
Chief, Quarantine and Border Health Services Branch
Division of Global Migration and Quarantine
Centers for Disease Control and Prevention

  • Webinar/Audio conference call on Thursday, March 28, 2019: 2:00 – 3:00 PM ET
  • Web-on-demand training will be available a few days after the live call.

A few minutes before the webinar begins, please click the link below to join the webinar:
https://zoom.us/j/275324866external icon

Or iPhone one-tap :
US: +16468769923,,275324866# or +16699006833,,275324866#
Or Telephone:
Dial(for higher quality, dial a number based on your current location):
US: +1 646 876 9923 or +1 669 900 6833
Webinar ID: 275 324 866
International numbers available: https://zoom.us/u/anixAVglVexternal icon

No additional resources available at this time.

WC2922 0387-0000-19-085-L04-P (must be completed by April 29, 2019)
WD2922 0387-0000-19-085-H04-P (must be completed by April 30, 2021)

  • Physicians
  • Nurses
  • Pharmacists
  • Veterinarians
  • Physician Assistants
  • Health Educators
  • Other Clinicians
  • Contact Information:coca@cdc.gov
  • Support/Funding:Centers for Disease Control and Prevention, Emergency Risk Communication Branch
  • Method of Participation:You may participate in the educational activity by viewing the program information above.
  • Fees: COCA Continuing Education (CE) is free.

Accreditation Statements

CME: The Centers for Disease Control and Prevention is accredited by the Accreditation Council for Continuing Medical Education (ACCME®) to provide continuing medical education for physicians.

The Centers for Disease Control and Prevention designates this live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

CNE: The Centers for Disease Control and Prevention is accredited as a provider of Continuing Nursing Education by the American Nurses Credentialing Center’s Commission on Accreditation.

This activity provides 1.0 contact hour.

CEU: The Centers for Disease Control and Prevention is authorized by IACET to offer 0.1 CEU’s for this program.

CECH: Sponsored by the Centers for Disease Control and Prevention, a designated provider of continuing education contact hours (CECH) in health education by the National Commission for Health Education Credentialing, Inc. This program is designated for Certified Health Education Specialists (CHES) and/or Master Certified Health Education Specialists (MCHES) to receive up to total 1 Category I continuing education contact hours. Maximum advanced level continuing education contact hours available are 0. CDC provider number 98614.

Image of acpe logo.CPE:The Centers for Disease Control and Prevention is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

This program is a designated event for pharmacists to receive) 0.1 CEUs in pharmacy education. The Universal Activity Number is 0387-0000-19-085-L04P and enduring 0387-0000-19-085-H04-P course category.

This activity has been designated as Knowledge-Based.

Once credit is claimed, an unofficial statement of credit is immediately available on TCEOnline. Official credit will be uploaded within 60 days on the NABP/CPE Monitor.

For Certified Public Health Professionals (CPH)

The Centers for Disease Control and Prevention is a pre-approved provider of Certified in Public Health (CPH) recertification credits and is authorized to offer 1 CPH recertification credit for this program.

AAVSB/RACE:This program was reviewed and approved by the AAVSB RACE program for 1.0 hours of continuing education. Participants should be aware that some boards have limitations on the number of hours accepted in certain categories and/or restrictions on certain methods of delivery of continuing education. Please contact the AAVSB RACE program if you have any comments/concerns regarding this program’s validity or relevancy to the veterinary profession.

DISCLOSURE: In compliance with continuing education requirements, CDC, our planners, our presenters, and their spouses/partners wish to disclose they have no financial interests or other relationships with the manufacturers of commercial products, suppliers of commercial services, or commercial supporters. Planners have reviewed content to ensure there is no bias.

Content will include discussion of the unlabeled use of a product and a product under investigational use, as this webinar will focus on the new treatment guidelines for severe malaria in the U.S. as starting April 1, 2019, there will be no FDA-approved, commercially available intravenous (IV) antimalarial for the treatment of severe malaria in the United States. IV artesunate, the WHO-recommended first-line drug for severe malaria is not FDA approved but is available through CDC under an expanded access investigational new drug (IND) protocol. IV artesunate will be the only option in the United States for treatment of severe malaria

CDC did not accept commercial support for this continuing education activity.

Page last reviewed: March 6, 2019